Q3 2024 Earnings Call Transcript November 7, 2024 MannKind Corporation beats earnings expectations. Reported EPS is $0.05, ...

MannKind will host a conference call and presentation webcast to discuss these results today at 4:30 p.m. Eastern Time. The webcast will be accessible via a link on MannKind’s website. A replay will ...

MannKind Corporation ( (MNKD) ) has released its Q3 earnings. Here is a breakdown of the information MannKind Corporation presented to its ...

MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2024 financial results will be released after market ...

Good Afternoon and welcome to the Mannkind Corporation third quarter, 2024 financial results earnings call. As a reminder, this call is being recorded on November 7, 2024. And we'll be available ...

MannKind completes phase 1 trial of nintedanib DPI for pulmonary fibrotic diseases: Danbury, Connecticut Tuesday, November 5, 2024, 16:00 Hrs [IST] MannKind Corporation, a company ...

MannKind Corporation (NASDAQ: MNKD) 公布了2024年第三季度强劲的财务业绩,收入同比增长37%,并取得重要的临床进展。公司首席执行官Michael Castagna强调了Tyvaso DPI合作项目的强劲表现以及Afrezza处方量的稳步上升。公司拥有2.68亿美元的现金储备,第三季度非GAAP营业收入为1500万美元,这使MannKind有能力推进其临床研发管 ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsMichael Castagna - CEOChris Prentiss ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended September 30, 2024.

Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported with oral nintedanibExpect to meet with the FDA in 1H ...